Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

“We look forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding ... Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our ...

Genomics, Inc. , a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, ...

Gilead Sciences, Inc. (Nasdaq ... forward to sharing new research that highlights the breadth of our antiviral portfolio and expanding pipeline as we strive to treat, prevent, cure and help ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...